HomeAGIO • NASDAQ
add
Agios Pharmaceuticals Inc
Previous close
$36.21
Day range
$35.09 - $37.86
Year range
$23.42 - $62.58
Market cap
2.19B USD
Avg Volume
893.55K
P/E ratio
3.42
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | 12.46M | 44.57% |
Operating expense | 45.87M | 29.08% |
Net income | -112.02M | -16.54% |
Net profit margin | -899.40 | 19.39% |
Earnings per share | -1.93 | -14.20% |
EBITDA | -125.80M | -20.70% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 938.94M | 64.76% |
Total assets | 1.47B | 90.31% |
Total liabilities | 101.68M | -9.66% |
Total equity | 1.37B | — |
Shares outstanding | 58.10M | — |
Price to book | 1.53 | — |
Return on assets | -20.99% | — |
Return on capital | -21.62% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | -112.02M | -16.54% |
Cash from operations | -77.12M | -6.25% |
Cash from investing | 78.97M | 112.02% |
Cash from financing | 65.00K | -94.09% |
Net change in cash | 1.91M | 105.57% |
Free cash flow | -51.97M | -32.43% |
About
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
Founded
2008
Website
Employees
487
